Introduction
============

Bladder cancer is one of the most common cancers worldwide, with 429,000 newly diagnosed bladder cancer patients in 2012.[@b1-ott-11-8359] It is reported that North America, Europe, and North Africa had the higher incidence of bladder cancer than other regions.[@b2-ott-11-8359] In addition, some studies have found that some environmental factors such as smoking, exposure to toxic industrial chemicals and gases, several medications of bladder cancer treatment, and genetic variations were all the risk factors for bladder cancer.[@b3-ott-11-8359],[@b4-ott-11-8359] Painful urination, blood in urine, and frequent urination were the early symptoms of bladder cancer. Thirty percent of new bladder cancer patients were initially diagnosed with a lethal phenotype of muscle invasive, while approximately 70% of bladder tumors were non-muscle invasive. In addition, approximately 25% non-muscle-invasive bladder cancer would progress to muscle-invasive disease. Because metastatic and muscle-invasive bladder cancer patients had higher mortality, surgery, radiation therapy, and chemotherapy were usually used in the multidisciplinary care.[@b5-ott-11-8359] Cisplatin-based chemotherapy, methotrexate, vinblastine, adriamycin, and cisplatin (M-VAC) regimen, and the doublet of gemcitabine and cisplatin (GC) represented the common therapeutic regimen for the bladder cancer patients in advanced stage.[@b6-ott-11-8359] In recent years, targeted therapeutics have been studied and applied in several malignancies such as gastric cancer, colorectal cancer, and lung cancer. For example, VEGF inhibitors and EGFR inhibitors were often used to treat several cancers. Although environmental factors played an important role in the occurrence of bladder cancer, many genetic alterations were also found in many studies of bladder cancer. Genomic alterations in fıbroblast growth factor receptor 3 (FGFR3) and other receptor tyrosine kinase (RTK) activation were found in the non-muscle-invasive bladder cancers.[@b6-ott-11-8359] In addition, there was evidence that the signal of PI3K/AKT/mTOR often produced many genetic alternations in bladder cancer cells.[@b7-ott-11-8359] Previous studies have identified a lot of somatic copy-number alterations such as *E2F3*, *PPARG*, *EGFR*, *MDM2*, *CCND1*, *CDKN2A*, and *RB1*.[@b8-ott-11-8359],[@b9-ott-11-8359] In addition, studies of sequencing in bladder cancer have identified many gene mutations in *TP53*, *PIK3CA*, *TSC1*, *HRAS*, and *RB1*.[@b8-ott-11-8359],[@b9-ott-11-8359] In these candidate genes, *KDM6A*, *EP300*, *CREBBP*, and *ARID1A*, chromatin remodeling genes, processed a frequency of \>10% in bladder cancer.[@b10-ott-11-8359] These advances in genetics of cancers improved the clinical management and prognosis of bladder cancer. In addition, the molecular biomarkers have been used for the early diagnosis and treatment of solid tumor. However, more diagnostic molecular biomarkers are still needed and combined to find the bladder cancer in the early stage.

*APC* gene consists of 15 exons, locating on 5q21-q22 and encoding a large multidomain protein which contains 2,843 amino acids, which are involved in the Wnt signaling pathway.[@b11-ott-11-8359] This gene was found in 1991 which was responsible for familial adenomatous polyposis (FAP).[@b12-ott-11-8359] The multifunctional protein was expressed widely in various tissues, especially in intestine and central nervous tissues. APC protein can combine with glycogen synthesis kinase 3β (GSK-3β) to form a complex named "destruction complex", which resulted in the degradation of β-catenin in the cytoplasm.[@b13-ott-11-8359] Immunoprecipitation was first used to explore the function of APC protein, and the precipitation of β-catenin was found, which suggested an important role of APC protein in Wnt signaling pathway.[@b13-ott-11-8359] Furthermore, APC protein could act as a regulatory factor to regulate cell migration, cell cycle, DNA replication and repair, and cell apoptosis.[@b14-ott-11-8359] In addition, APC protein can act as a checkpoint from the G0/G1 phase to the S phase in the process of cell cycle and repress the infinite proliferation of cancer cells.[@b14-ott-11-8359] Therefore, APC protein possessed the function of tumor inhibition, and its inactivation was often found in many cancers such as thyroid cancer, breast cancer, and colorectal cancer.[@b15-ott-11-8359]

Although many studies that evaluated the association of *APC* promoter methylation with bladder cancer risk had been published, it was still needed to summarize these published data to get a more accurate result. Furthermore, evidence was still lacking from the present studies that assessed the role of *APC* promoter hypermethylation in bladder cancer risk. As a consequence, to assess the potential role of *APC* promoter hypermethylation in the risk and pathogenesis of bladder cancer, we performed this meta-analysis.

Materials and methods
=====================

Search strategy
---------------

According to the PRISMA statement, literatures that assessed the associations of *APC* promoter hypermethylation with bladder cancer risk and clinical characteristics were searched from the relevant databases including PubMed, Web of Science, Wanfang, Vapp, and CNKI (Chinese National Knowledge Infrastructure).[@b16-ott-11-8359] The following strategies were used: (bladder cancer OR bladder carcinoma OR bladder neoplasms OR carcinoma of urinary bladder) AND (*APC* OR Adenomatous polyposis coli OR Adenomatous polyposis coli gene). Furthermore, the retrieval words were applied with "methylation", "hypermethylation", and "epigenetic". Meanwhile, the relevant references of included original articles and reviews were scanned to identify additional eligible studies. The latest update of literature searching was conducted in March 2017.

Inclusion and exclusion criteria
--------------------------------

The inclusion criteria for the eligible studies were as follows: 1) original case--control studies that assessed the association between *APC* promoter hypermethylation and bladder cancer risk and contained sufficient data of *APC* promoter hypermethylation frequency in controls and cases; 2) studies that were published in English or Chinese language; 3) eligible studies that contained diagnostic criteria of bladder cancer patients; and 4) studies that declared source of controls. In addition, duplicate or studies that did not obey the inclusion criteria were excluded.

Data extraction
---------------

According to the inclusion criteria, two researchers independently extracted the data from the eligible studies. The frequency of *APC* promoter hypermethylation in cases and controls was extracted to calculate OR and 95% CI. The additional information was extracted, such as first author, publication year, pTNM stage and grade of bladder cancer patients, detection method of *APC* promoter hypermethylation, study design type, sample type, and ethnicity. The Newcastle--Ottawa Scale (NOS; <http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp>) was used to evaluate the qualities of included studies.[@b17-ott-11-8359] Studies with scores 7--9 were considered as high-quality studies, and those with scores 4--6 were defined as medium-quality studies.

Statistical analyses
--------------------

The frequency of *APC* promoter hypermethylation in healthy controls and cases was accumulated to calculate OR and 95% CI. Subgroup analysis based on ethnicity and sample type was performed to investigate the strength of correlation between *APC* promoter hypermethylation and bladder cancer risk. *Q* statistic and *I*^2^ value were applied to evaluate the statistical heterogeneity among studies.[@b17-ott-11-8359],[@b18-ott-11-8359] If *P*-value of *Q* test was \<0.05 which indicated a significant heterogeneity, the random-effects model was used. If *P*-value of *Q* test was ≥0.05, the fixed-effects model was selected.[@b19-ott-11-8359],[@b20-ott-11-8359] The possibility of publication bias was assessed with Begg's test and Egger's test (*P*\<0.05 indicated a significant publication bias).[@b21-ott-11-8359],[@b22-ott-11-8359] To validate the stability of results and eliminate the individual heterogeneous study, sensitivity analysis was carried out by sequentially removing each study. If the overall OR had a big change after one study was omitted, this study would be eliminated and the overall OR would be recalculated. In addition, the summarized sensitivity, specificity, and the summary receiver operator characteristic (SROC) curve (area under the curve, AUC) values were calculated to evaluate the value of the diagnostic value of APC promoter hypermethylation in bladder cancer.[@b23-ott-11-8359] All statistical analyses were carried out using STATA 12.0 (StataCorp LP, College Station, TX, USA) software, and *P*-values were two sided in this meta-analysis.

Results
=======

Study characteristics
---------------------

In total, 229 literatures were identified from the initial searching, in which 100 articles were duplicate and were excluded. In the remaining 129 articles, 11 articles were reviewed and removed. Then, 118 studies were remained after titles and abstracts were scanned. Of the 118 articles with full-text format, 94 literatures were excluded since they did not involve the association between *APC* promoter hypermethylation and bladder cancer risk. In the process of data extracting, 10 articles were eliminated due to insufficient data of *APC* promoter hypermethylation in controls and cases. Thus, 14 studies were enrolled including 531 controls and 1,293 cases in the final meta-analysis. The main characteristics of eligible studies are presented in [Table 1](#t1-ott-11-8359){ref-type="table"}. From the 14 studies, 13 articles were in English language and one article was in Chinese language.[@b24-ott-11-8359]--[@b37-ott-11-8359] Eleven studies were conducted in Caucasians, two studies were in Asians, and one study was in mixed population. Thirteen studies were included for the diagnostic meta-analysis.[@b24-ott-11-8359]--[@b36-ott-11-8359] The sample type of case group included serum, urine, and tissue of bladder cancer patients (TBCPs); the sample in the control group consisted of serum, urine, and tissue of healthy people. Methylation-specific PCR (MSP) was adopted in most included studies, and only one study applied quantitative MSP (qMSP; [Figure 1](#f1-ott-11-8359){ref-type="fig"}).

Quality score assessment
------------------------

[Table 1](#t1-ott-11-8359){ref-type="table"} summarizes the methodological quality of the included studies. Thirteen studies that obtained scores of 6--9 were regarded as medium or high quality. However, one study did not contain healthy control; therefore, the evaluation of methodological quality was not carried out in that study.

Meta-analysis results
---------------------

The cumulative results of 13 studies, involving in 1,189 bladder cancer patients, indicated a significant relationship between *APC* promoter hypermethylation and bladder cancer risk (OR =17.01, 95% CI =7.40--39.07). This result revealed that people with *APC* promoter hypermethylation had an elevated bladder cancer risk than those with *APC* promoter hypomethylation. Statistical heterogeneity was observed in the meta-analysis (*I*^2^ =62.5%, *P*=0.001); thus, random-effects model was selected. Stratified analysis based on ethnicity and sample type was also performed to decrease the effect of heterogeneity on the overall OR. Significant differences were found in the pooled OR of two subgroups based on sample type (urine of bladder cancer patients \[UBCPs\]: OR =35.92, 95% CI =5.53--233.16; TBCPs: OR =11.58, 95% CI =3.79--35.36). In addition, the pooled meta-analysis showed that individuals with APC promoter hypermethylation had a higher grade than individuals with *APC* promoter hypomethylation (OR =4.11, 95% CI =1.62--10.43). No association between *APC* promoter hypermethylation and pTNM stage of bladder cancer was observed (OR =1.84, 95% CI =0.87--3.93). In the analysis about clinical information, random-effects model and subgroup analysis based on sample type were used because of the significant statistical heterogeneity. The heterogeneity was reduced in the stratified analysis, and the results are shown in [Figures 2](#f2-ott-11-8359){ref-type="fig"}[](#f3-ott-11-8359){ref-type="fig"}--[4](#f4-ott-11-8359){ref-type="fig"} ([Tables 2](#t2-ott-11-8359){ref-type="table"} and [3](#t3-ott-11-8359){ref-type="table"}). In addition, we also discussed the relationship between the grade of bladder cancer and *APC* gene promoter hypermethylation in non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. But no significant associations were found (non-muscle-invasive bladder cancer: OR =1.14, 95% CI =0.61--2.14; muscle-invasive bladder cancer: OR =1.54, 95% CI =0.81--2.94).

Publication bias and sensitivity analyses
-----------------------------------------

The funnel plot of the relationship between *APC* promoter hypermethylation and bladder cancer risk is shown in [Figure 4](#f4-ott-11-8359){ref-type="fig"}. *P*-value of Begg's test and Egger's test was 0.088 and 0.001, respectively. Meanwhile, *P*-value of Begg's test and Egger's test, assessing the association between *APC* promoter hypermethylation and grade of bladder cancer, was 0.099 and 0.007, respectively. In addition, publication bias was found based on the result of Egger's test, while the result of Begg's test indicated that no publication bias was found. Thus, we carried out sensitivity analyses by omitting individual study at each time. Interestingly, the overall OR was between 13.91 (95% CI =6.42--30.15) and 20.87 (95% CI =9.28--46.95), which indicated that the positive result was stable. According to the results of subgroup analysis, sample type and ethnicity might partly lead to the publication bias. In the subgroup analysis of TBCPs for bladder cancer risk, *P*-value of Begg's test and Egger's test was 0.497 and 0.270, respectively. In addition, in the subgroup analysis of Caucasians for the grade of bladder cancer, *P*-value of Begg's test and Egger's test was 0.188 and 0.036, respectively. No significant publication bias was found in the analysis of association between *APC* promoter hypermethylation and the pTNM stage of bladder cancer (Begg's test, *P*=0.652; Egger's test, *P*=0.208). Finally, to eliminate the publication bias and achieve an accurate and stable pooled OR, we conducted the trim-and-fill analysis using random-effects model. The adjusted OR was 7.70 with 95% CI of 3.60--16.47, which indicated a significant association between *APC* promoter hypermethylation and bladder cancer risk ([Figure 5](#f5-ott-11-8359){ref-type="fig"}).

Diagnostic capacity of APC hypermethylation in bladder cancer vs normal controls
--------------------------------------------------------------------------------

The diagnostic value of APC hypermethylation as a potential biomarker in the bladder cancer was assessed. In addition, the pooled sensitivity, specificity, and AUC values of APC hypermethylation were 0.52 (95% CI =0.41--0.63), 0.98 (95% CI =0.90--1.00), and 0.80 (95% CI =0.76--0.83), respectively. The SROC curve with an AUC value and the forest plot of sensitivity and specificity are shown in [Figures 6](#f6-ott-11-8359){ref-type="fig"} and [7](#f7-ott-11-8359){ref-type="fig"}, respectively. Furthermore, the likelihood ratio scattergram was drawn to evaluate the diagnostic value of APC hypermethylation in the bladder cancer patients and controls ([Figure 8](#f8-ott-11-8359){ref-type="fig"}).

Discussion
==========

Promoter hypermethylation of *APC* gene might result in the downregulation of *APC* protein expression and increase the cancer risk. It has been reported that the inactivity of *APC* protein was associated with the accumulation of β-catenin, which affected the growth of cancer cells.[@b38-ott-11-8359] Previous studies have explored the association between *APC* promoter hyper-methylation and cancer risk, including colorectal cancer, breast cancer, prostate cancer, and non-small-cell lung cancer.[@b39-ott-11-8359]--[@b42-ott-11-8359] According to the study of breast cancer, *APC* promoter hypermethylation had a significant association with the grade of breast cancer.[@b43-ott-11-8359] Meanwhile, the downregulation of *APC* expression or *APC* promoter hypermethylation was related to the formation of colorectal cancer.[@b44-ott-11-8359] Therefore, *APC* gene, as a well-characterized tumor suppressor gene, was an effective diagnostic factor for various tumors. Although several studies were performed to explore the correlation between *APC* promoter hypermethylation and bladder cancer risk, no cumulative meta-analysis was performed. Therefore, we conducted this meta-analysis to investigate the potential role of *APC* promoter hypermethylation in bladder cancer risk.

The results based on the overall pooled OR suggested that the frequency of *APC* promoter hypermethylation in cases was higher than that in healthy controls. However, evident heterogeneity of included studies was presented in this meta-analysis. As a consequence, subgroup analysis based on sample type and ethnicity was performed to explore the source of heterogeneity. The results showed that ethnicity and sample type contributed a lot to the heterogeneity among studies. In subgroup analysis based on sample type and significant association between *APC* promoter hypermethylation and bladder cancer pathogenesis was found in tissue sample and urine sample. In previous reports, DNA was extracted from tissue sample and urine sample to detect the level of *APC* promoter methylation; however, these results often produced false-negative and false-positive results in urine sample compared with tissue sample.[@b27-ott-11-8359],[@b36-ott-11-8359] Therefore, the frequency of *APC* promoter hypermethylation in tissue and urine had a tiny difference, in which the pooled OR was 35.92 in tissue sample and 11.58 in urine sample. The subgroup analysis based on methylation detection methods was not performed since most studies used MSP and only one study applied the detection method of qMSP. Furthermore, subgroup analysis based on ethnicity was conducted, which indicated a significant association between *APC* promoter hypermethylation and bladder cancer risk in both Caucasians and Asians. The results of sensitivity analysis showed that although many environmental factors and other genetic factors existed, the positive correlation was still robust and stable. The trim-and-fill analysis was performed due to significant publication bias, which showed a significant adjusted OR. In addition, we found that the status of *APC* promoter hypermethylation in bladder cancer patients with advanced stage was significantly increased compared with early-stage patients. This result demonstrated that *APC* promoter hyper-methylation might be associated with the malignant evolution of bladder cancer. The similar results were found in breast cancer patients.[@b38-ott-11-8359] As mentioned earlier, the results of four studies indicated a significant association of *APC* promoter hypermethylation with grade of bladder cancer.[@b25-ott-11-8359],[@b27-ott-11-8359],[@b31-ott-11-8359],[@b37-ott-11-8359] In addition, three studies detected negative results.[@b24-ott-11-8359],[@b29-ott-11-8359],[@b36-ott-11-8359] From the meta-analysis, we found no significant association between *APC* promoter hypermethylation and pTNM stage of bladder cancer in Caucasians and Asians. Surprisingly, only *P*-value of Egger's linear regression was \<0.05, which showed an evident publication bias. Egger et al[@b45-ott-11-8359] reported that Egger's test was more sensitive than Begg's test. The publication bias might result from many factors such as sample type, smoking, source of funding, other genetic alternations, used medicine in the treatment of bladder cancer, and other complications. It is worth mentioning that non-English articles were not included in this meta-analysis, which might partly lead to the publication bias in this meta-analysis. However, the large sample size of included studies ensured the reliability of results and reduced the publication bias. In addition, according to the published articles, we summed up an interaction profiling of proteins with APC protein. These genes might be changed in different degrees in the development of bladder cancer. For instance, the hypermethylation of ARHGEF4 gene promoter was found in the sample of bladder cancer.[@b46-ott-11-8359] On the basis of the published literatures, KCTD1 decreased the expression of β-catenin in Hela cell, and APC protein affected the process.[@b45-ott-11-8359] Moreover, some studies also found that genetic variants in the wnt/β-catenin (CTNNB1) signaling pathway have been implicated in the development of bladder cancer.[@b48-ott-11-8359] So, according to the present result of the meta-analysis and the published articles, these proteins including ARHGEF4, CTNNB1, KCTD1, CTNNA1, KHDRBS1, IQGAP1, and FRAT1 might have close relationships with APC protein and might be involved in the development of bladder cancer.[@b46-ott-11-8359]--[@b51-ott-11-8359]

To explore whether APC hypermethylation is an effective diagnostic marker, diagnostic analysis was also conducted. From the results, significant statistical differences were found in the analysis of sensitivity and specificity. According to the summarized results of likelihood ratio scattergram, the APC hypermethylation was really useful for the diagnosis of bladder cancer. However, APC gene was commonly studied as a tumor suppressor gene in several cancers. Therefore, APC hypermethylation may be a universal biomarker for several cancers. In the future studies, it is very necessary to perform more studies evaluating the associations between APC hypermethylation and the development of some common tumors. In addition, the most important is that we should systematically analyze the role of APC hypermethylation in various cancers.

Although significant association between APC hypermethylation and bladder cancer was found, the present study still had some limitations. First, the sample size in Asian populations was too small to evaluate the association between *APC* promoter hypermethylation and bladder cancer risk. Second, no environmental factors were included in this study because of few environmental information in original articles. Third, although we collected all data from eligible studies, the combined sample size was still small, which might increase the risk of publication bias and lower the stability of results. Fourth, the methodological quality of included studies was inconsistent, which might result in an obvious heterogeneity among eligible studies. Thus, future large-scale and higher-quality studies, including more environmental information, should be performed.

Conclusion
==========

This was the first meta-analysis to evaluate the association between *APC* promoter hypermethylation and bladder cancer risk. The current evidence revealed that *APC* promoter hypermethylation was significantly associated with the risk of bladder cancer. In addition, there was a significant correlation between *APC* promoter hypermethylation and the grade of bladder cancer. More importantly, we discovered that APC hypermethylation has the potential to be a biomarker to diagnose bladder cancer according to the present meta-analysis. Therefore, more studies with larger size and clinical information are still needed to be performed to confirm these results in the future.
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![Forest plot of the association between APC promoter hypermethylation and bladder cancer risk.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** SBCP, serum of bladder cancer patients; TBCP, tissue of bladder cancer patients; UBCP, urine of bladder cancer patients.](ott-11-8359Fig2){#f2-ott-11-8359}

![Forest plot of the association between APC promoter hypermethylation and grade of bladder cancer.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** TBCP, tissue of bladder cancer patients; UBCP, urine of bladder cancer patients.](ott-11-8359Fig3){#f3-ott-11-8359}

![Forest plot of the association between APC promoter hypermethylation and pTNM stage of bladder cancer.\
**Note:** Weights are from random-effects analysis.\
**Abbreviations:** TBCP, tissue of bladder cancer patients; UBCP, urine of bladder cancer patients.](ott-11-8359Fig4){#f4-ott-11-8359}

![Trim-and-fill funnel plot of the association between APC promoter hypermethylation and bladder cancer risk.\
**Abbreviation:** SE, standard error.](ott-11-8359Fig5){#f5-ott-11-8359}

![The SROC curve based on APC hypermethylation.\
**Abbreviations:** AUC, area under the curve; SENS, sensitivity; SPEC, specificity; SROC, summary receiver operator characteristic.](ott-11-8359Fig6){#f6-ott-11-8359}

![Forest plot of sensitivity and specificity of APC hypermethylation for the diagnosis of bladder cancer.](ott-11-8359Fig7){#f7-ott-11-8359}

![Likelihood ratio scattergram for the diagnosis value of APC methylation in bladder cancer.\
**Abbreviations:** LRN, negative likelihood ratio; LRP, positive likelihood ratio; LUQ, left upper quadrant; RUQ, right upper quadrant.](ott-11-8359Fig8){#f8-ott-11-8359}

###### 

Characteristics of the included studies

  Study                                Year   Language   Location          Race         Study design    Sample type   Control type   Method   Control   Case   Score         
  ------------------------------------ ------ ---------- ----------------- ------------ --------------- ------------- -------------- -------- --------- ------ ------- ----- ----
                                                                                                                                                                             
  Pietrusinski[@b24-ott-11-8359]       2017   English    Poland            Caucasians   Retrospective   UBCP          UHP            MSP      100       0      60      53    6
  Bilgrami et al[@b25-ott-11-8359]     2014   English    Pakistan          Caucasians   Retrospective   TBCP          THP            MSP      10        0      22      54    6
  Hauser et al[@b26-ott-11-8359]       2013   English    Germany           Caucasians   Retrospective   SBCP          SHP            MSP      48        5      43      52    7
  Berrada et al[@b27-ott-11-8359]      2012   English    Morocco           Caucasians   Retrospective   UBCP          UHP            MSP      10        2      6       23    6
  Zuiverloon et al[@b28-ott-11-8359]   2012   English    the Netherlands   Caucasians   Retrospective   TBCP          UHP            MSP      40        0      28      6     6
  Eissa et al[@b29-ott-11-8359]        2011   English    Egypt             Mixed        Retrospective   UBCP          UHP            MSP      128       0      196     125   6
  Chen et al[@b30-ott-11-8359]         2011   English    China             Asians       Retrospective   TBCP          UHP            MSP      19        0      75      53    6
  Pan et al[@b31-ott-11-8359]          2010   Chinese    China             Asians       Retrospective   TBCP          THP            MSP      12        3      19      91    6
  Yates et al[@b32-ott-11-8359]        2007   English    England           Caucasians   Retrospective   TBCP          THP            qMSP     29        1      66      30    6
  Hoque et al[@b33-ott-11-8359]        2006   English    American          Caucasians   Retrospective   UBCP          UHP            MSP      25        0      3       8     7
  Neuhausen et al[@b34-ott-11-8359]    2006   English    Germany           Caucasians   Retrospective   TBCP          THP            MSP      14        5      53      43    6
  Yates et al[@b35-ott-11-8359]        2006   English    England           Caucasians   Retrospective   UBCP          UHP            MSP      57        11     21      14    6
  Dulaimi et al[@b36-ott-11-8359]      2004   English    American          Caucasians   Retrospective   UBCP          UHP            MSP      12        0      20      25    6
  Serizawa et al[@b37-ott-11-8359]     2011   English    Denmark           Caucasians   retrospective   UBCP          NR             MSP      NR        NR     NR      NR    NR

**Abbreviations:** M, methylation; MSP, methylation-specific PCR; NR, not reported; qMSP, quantitative MSP; SBCP, serum of bladder cancer patients; SHP, serum of healthy people; TBCP, tissue of bladder cancer patients; THP, tissue of healthy people; U, unmethylation; UBCP, urine of bladder cancer patients; UHP, urine of healthy people.

###### 

Characteristics of the included studies for TNM stage of bladder cancer

  Study                              Year   Language   Location   Race         Study design    Sample type   Method   T0--T1   T2--T4        
  ---------------------------------- ------ ---------- ---------- ------------ --------------- ------------- -------- -------- -------- ---- ----
                                                                                                                                             
  Pietrusinski[@b24-ott-11-8359]     2016   English    Poland     Caucasians   Case--control   UBCP          MSP      52       38       8    15
  Berrada et al[@b27-ott-11-8359]    2012   English    Morocco    Caucasians   Retrospective   UBCP          MSP      6        16       0    7
  Eissa et al[@b29-ott-11-8359]      2011   English    Egypt      Mixed        Case--control   UBCP          MSP      133      88       63   37
  Pan et al[@b31-ott-11-8359]        2010   Chinese    China      Asians       Case--control   TBCP          MSP      17       31       2    60
  Dulaimi et al[@b36-ott-11-8359]    2004   English    America    Caucasians   Case--control   UBCP          MSP      12       14       8    11
  Serizawa et al[@b37-ott-11-8359]   2011   English    Denmark    Caucasians   Retrospective   TBCP          MSP      66       20       13   6
  Serizawa et al[@b37-ott-11-8359]   2011   English    Denmark    Caucasians   Retrospective   TBCP          MSP      5        20       2    4

**Abbreviations:** M, methylation; MSP, methylation-specific PCR; TBCP, tissue of bladder cancer patients; U, unmethylation; UBCP, urine of bladder cancer patients.

###### 

Statistical analysis of association between APC hypermethylation and bladder cancer carcinogenesis

  Variable     Study (n)   OR      95% CI         Heterogeneity   
  ------------ ----------- ------- -------------- --------------- -------
                                                                  
  Caucasians   10          13.4    5.44--33.05    60.8            0.006
  Asians       2           20.52   6.03--69.81    0.00            0.794
  Grade        7           4.11    1.62--10.43    74.5            0.001
  pTNM stage   7           1.84    0.87--3.93     65.2            0.008
  TBCP         6           11.58   3.79--35.36    48.9            0.081
  UBCP         6           35.92   5.53--233.16   78.5            0.000
  Total        13          17.01   7.40--39.07    62.5            0.001

**Abbreviations:** TBCP, tissue of bladder cancer patients; UBCP, urine of bladder cancer patients.
